Xeris Biopharma stock rises 1.62 percent on September 24

Xeris Biopharma stock was trading at USD 8.80 on Nasdaq on September 24, 2026 at 1:10 p.m. ET, up 1.62 percent. The latest operating figures show revenue growth alongside a wider earnings gap.

Revenue growth reaches 29 percent

Xeris reported Q2 2026 revenue of USD 92.1 million, up 29 percent year over year, while net product revenue reached USD 91.0 million, up 34 percent. The figures were reported in the Q2 earnings call transcript published by The Globe and Mail.

Gross margin reached 86 percent in Q2 2026, an improvement of 400 basis points from the prior-year quarter. Full-year revenue guidance was set at USD 385 million to USD 390 million, giving investors a measurable framework for the commercial ramp.

XP-8121 sets a late 2026 test

Xeris outlined a development path for XP-8121, its investigational once-weekly subcutaneous levothyroxine treatment. The company expects to begin the Phase 3 Cornerstone study by year-end 2026, according to an 8-K summary published by Stock Titan on September 9, 2026. That timeline makes development execution the next quantified checkpoint beyond the marketed portfolio.

Nasdaq quote gains 1.62 percent

The USD 8.80 Nasdaq quote on September 24, 2026 stood 12.70 percent below the 52-week high of USD 10.08 and USD 3.55 above the 52-week low of USD 5.25. Market capitalization was USD 1,519,249,600 on the same date.

Valuation expectations remain higher than the share price. MarketBeat reported on September 21, 2026 that analysts held a consensus rating of Hold and an average price target of USD 12.80. The contrast between 29 percent revenue growth and the Hold consensus leaves execution against guidance as the central market test.